-

09:24:08 AM

CLLS Stock News

CLLS - Cellectis

10/19/21 4:30 PM

Nasdaq : CLLS

clinical trial

Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021

Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic diseases, in

RHEA-AI

neutral

10/12/21 4:35 PM

Nasdaq : CLLS

conferencesclinical trial

Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic diseases,

RHEA-AI

neutral

10/11/21 4:30 PM

Nasdaq : CLLS

Monthly information on share capital and company voting rights

Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the capital Total number of voting rights 09/30/2021 45,465,310 51,066,417 About

RHEA-AI

neutral

09/10/21 4:30 PM

Nasdaq : CLLS

Monthly information on share capital and company voting rights

Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the capital Total number of voting rights 08/31/2021 45,465,310 51,067,217 About

RHEA-AI

neutral

08/26/21 4:34 PM

Nasdaq : CLLS

Cellectis Announces Participation in Five Investor Conferences

Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for monogenic

RHEA-AI

neutral

08/05/21 4:30 PM

Nasdaq : CLLS

earnings

Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021

• Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed or refractory multiple myeloma patients. • Preclinical pipeline disclosed at Innovation Days : UCART20x22 for B-cell malignancies, UCARTMESO (targeting mesothelin), and TALGlobin01 (Sickle Cell Disease)

RHEA-AI

neutral

08/02/21 4:30 PM

Nasdaq : CLLS

Monthly information on share capital and company voting rights

Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the capital Total number of voting rights 07/31/2021 45,465,310 51,535,159 About

RHEA-AI

neutral

07/29/21 4:34 PM

Nasdaq : CLLS

Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du deuxième trimestre 2021 le vendredi 6 août à 14h00 CET

Cellectis S.A. (NASDAQ : CLLS – EURONEXT GROWTH : ALCLS) (la « Société »), une société d’édition du génome spécialisée dans les essais en immuno-oncologie en phase clinique utilisant des cellules T allogéniques à récepteur d’antigène chimérique (CAR) et

RHEA-AI

neutral

07/29/21 4:34 PM

Nasdaq : CLLS

earnings

Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT

Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR) T-cells and gene therapy programs for monogenic

RHEA-AI

neutral

07/12/21 4:30 PM

Nasdaq : CLLS

Monthly information on share capital and company voting rights

Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the capital Total number of voting rights 06/30/2021 45,461,310 51,531,339 About

RHEA-AI

neutral